Ipsen jumps on ADC bandwagon with deal for Sutro’s ROR1-targeting therapy

02 Apr 2024
ADCAcquisitionLicense out/inPhase 1
Ipsen added the first antibody-drug conjugate (ADC) to its pipeline through a deal with Sutro Biopharma potentially worth up to $900 million. Mary Jane Hinrichs, head of early development at Ipsen, suggested that Sutro’s STRO-003, which targets the ROR1 tumour antigen, has “best-in-class potential.”
Ipsen will assume responsibility for Phase I preparation activities for STRO-003 as well as  all subsequent clinical development and global marketing activities. In return, Sutro is eligible to receive around $90 million in near-term payments, including an equity investment, along with further milestone payments and tiered sales royalties.
Hinrichs noted that STRO-003 utilises Sutro’s site-specific technology to generate a highly stable conjugate, coupled with exatecan payloads, that have shown significant potential in solid tumours. The ADC is in the final stages of preclinical development.
Both Boehringer Ingelheim and Merck & Co. splashed out in 2020 to add ADCs targeting ROR1 to their pipelines. Merck’s asset, gained via the purchase of VelosBio, is currently in mid-stage development, but Boehringer, which added its therapy through the acquisition of NBE-Therapeutics, halted work on the drug last year.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.